CSRxP: PASSAGE OF CORNYN-BLUMENTHAL AND Q1/Q2 REFORMS WOULD BE POSITIVE STEPS TOWARD HOLDING BIG PHARMA ACCOUNTABLE FOR PATENT ABUSE
Bipartisan, Market-Based Solutions Would Crack Down on Big Pharma’s Patent… Read More
Bipartisan, Market-Based Solutions Would Crack Down on Big Pharma’s Patent… Read More
Lawmakers Must Act to Hold Big Pharma Accountable for Egregious Patent Abuse… Read More
Congress Should Not Further Consider Misguided Proposal That Would Enable More… Read More
Lawmakers Should Remain Focused on Holding Big Pharma Accountable for… Read More
Lawmakers Should Remain Focused on Holding Big Pharma Accountable for… Read More
Legislation Scheduled for Thursday Markup Would Encourage Adoption of… Read More
HELP Committee Hearing an Opportunity to Highlight Staggering Cost… Read More
Lowering Prices for Some Patients at Some Dosages Will Have Limited Impact,… Read More
Bipartisan, Market-Based Solution Would Help Crack Down on Anti-Competitive… Read More
Brand Name Drug Giants’ Average Price Increases for June-July Outpace Rate… Read More
Legislation Would Hold Big Pharma Accountable for Anti-Competitive Tactics… Read More
Latest Data Finds List Prices of Prescription Drug Prices Have Increased… Read More